

OPTICAL SENSORS INCORPORATED CHANGES NAME TO VÄSAMED, Inc.

MINNEAPOLIS, MN - June 22, 2007 – Optical Sensors Incorporated d/b/a väsamed (OPTL.PK), developer and supplier of non-invasive peripheral and cardiovascular diagnostic systems, today announced that it has changed its name to VÄSAMED, Inc.

“Since early 2004, Optical Sensors Incorporated has been doing business as “väsamed”, a name that underscores our mission to provide non-invasive diagnostic tools for a variety of peripheral vascular and cardio vascular conditions,” said Paulita LaPlante, president and chief executive officer. “In the course of bringing the SensiLase and AcQtrac diagnostic systems to market, our company has become known in the medical community as VÄSAMED and we have concluded that our corporate name should be changed to reflect this acceptance by our customers. Accordingly, under the laws of Delaware where we are incorporated, the holders of a majority of shares entitled to vote have consented to a change in our name to VÄSAMED, Inc. and our articles of incorporation have been amended to reflect this change.”

VÄSAMED is a medical technology company specializing in low-cost, non-invasive peripheral and cardiovascular diagnostic systems for hemodynamic assessment and monitoring. Products developed, manufactured and sold by VÄSAMED include the SensiLase™ PAD 3000 diagnostic system that determines skin perfusion pressure and pulse volume waveforms for quantitative assessment of microvascular health in patients with chronic foot ulcers, diabetes and other peripheral arterial disease. Currently, most of VÄSAMED’s revenues are from sales of the SensiLase product to wound care clinics, podiatrists, vascular surgeons and other health care providers. The Company also markets the non-invasive AcQtrac™ hemodynamic monitoring system that provides data required to better assess and direct the treatment of advanced heart failure, hypertension and other cardiovascular diseases. VÄSAMED’s third device, the MicroStat™ tissue capnometry system, non-invasively measures sublingual CO₂ and provides an early warning signal of diminished perfusion in tissue and possible organ failure.

For more information about VÄSAMED, see the company's web site at www.vasamed.com. The Company’s shares are traded on the Pink Sheets under the symbol OPTL.PK and its financial information is posted at www.pinksheets.com.

#####

PRESS RELEASE FROM:
VÄSAMED, Inc.
7615 Golden Triangle Drive
Minneapolis, MN 55344
Contact: Roberta Dircks, CFO
(952) 944-5857 ext. 542